CA
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVECOVER ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

CA Cancer J Clin 1995; 45:88
doi: 10.3322/canjclin.45.2.88
© 1995 American Cancer Society
This Article
Right arrow Full Text (PDF) Freely available
Right arrow Submit a letter to the editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Qazi, F.
Right arrow Articles by McGuire, W. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Qazi, F.
Right arrow Articles by McGuire, W. P.

CA: A Cancer Journal for Clinicians, Vol 45, Issue 2 88-101, Copyright © 1995 by American Cancer Society

ARTICLES

The treatment of epithelial ovarian cancer

F. Qazi and W. P. McGuire
Division of Hematology/Oncology, Emory University School of Medicine Atlanta, Georgia.

The treatment and long-term survival of patients with ovarian cancer varies by stage. At present, five-year survival for patients with early-stage disease ranges from 50 to 95 percent, while five-year survival for patients with advanced-stage disease is less than 25 percent. Several new drugs with significant activity in advanced-stage ovarian cancer offer hope for increased long-term survival in the future. This article reviews the current and experimental approaches to the treatment of all stages of ovarian cancer.


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
A. Okamoto, T. Nikaido, K. Ochiai, S. Takakura, M. Saito, Y. Aoki, N. Ishii, N. Yanaihara, K. Yamada, O. Takikawa, et al.
Indoleamine 2,3-Dioxygenase Serves as a Marker of Poor Prognosis in Gene Expression Profiles of Serous Ovarian Cancer Cells
Clin. Cancer Res., August 15, 2005; 11(16): 6030 - 6039.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Nishizuka, S.-T. Chen, F. G. Gwadry, J. Alexander, S. M. Major, U. Scherf, W. C. Reinhold, M. Waltham, L. Charboneau, L. Young, et al.
Diagnostic Markers That Distinguish Colon and Ovarian Adenocarcinomas: Identification by Genomic, Proteomic, and Tissue Array Profiling
Cancer Res., September 1, 2003; 63(17): 5243 - 5250.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. M. Fracasso, M. F. Brady, D. H. Moore, J. L. Walker, P. G. Rose, L. Letvak, T. M. Grogan, and W. P. McGuire
Phase II Study of Paclitaxel and Valspodar (PSC 833) in Refractory Ovarian Carcinoma: A Gynecologic Oncology Group Study
J. Clin. Oncol., June 15, 2001; 19(12): 2975 - 2982.
[Abstract] [Full Text] [PDF]

Home page
 Obstet GynecolHome page
C. P. GROSS, W. NICHOLSON, and N. R. POWE
Factors Affecting Prophylactic Oophorectomy in Postmenopausal Women
Obstet. Gynecol., December 1, 1999; 94(6): 962 - 968.
[Abstract] [Full Text] [PDF]

Home page
 Obstet GynecolHome page
K. A. ORIEL, E. M. HARTENBACH, and P. L. REMINGTON
Trends in United States Ovarian Cancer Mortality, 1979-1995
Obstet. Gynecol., January 1, 1999; 93(1): 30 - 33.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVECOVER ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1995 by American Cancer Society.